Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-CD52 antibody treatment for diabetes

A technology for CD52, diabetic patients, applied in the field of prevention and/or treatment of type 1 diabetes by CD52-specific antibodies

Inactive Publication Date: 2007-05-02
GENZYME CORP
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Presence of multiple anti-islet autoantibodies indicates high risk for developing diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0016] A. Clinical Evaluation - Prevention

[0017] Trials aimed at preventing progression in pre-diabetic individuals would preferably enroll first-degree relatives of individuals diagnosed with IDDM because they are at least 10-fold more at risk of developing clinical IDDM than the general population (Tarn et al., 1988). Eligibility also includes that the patient is islet cell antibody (ICA) positive, for example, if the patient exhibits ICA > 20 Juvenile Diabetes Foundation (JDF) units in the patient's serum. ICA was determined by indirect immunofluorescence on cryosections of human pancreas (Lampeter et al., 1994; Becker et al., 1990). Other useful surrogate markers indicative of β-cell destruction processes include glutamate decarboxylase (GAD) and transmembrane protein tyrosine phosphatase (IA-2) and can be used to screen the general population (Pozzilli et al., 2001). The binding of GAD and IA-2 antibodies has high specificity for IDDM, especially in patients older tha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides for the prevention and / or treatment of Type 1 diabetes mellitus with CD52 specific antibodies, e.g. CAMPATH-1H.

Description

technical field [0001] The present invention relates to the use of CD52 specific antibody in preventing and / or treating type 1 diabetes. Background technique [0002] Type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) is a chronic, organ-specific autoimmune disease caused by the selective destruction of insulin-producing islet beta cells in the pancreas. In humans, several years are typically taken from the diagnosis of the disease to the progression to complete destruction of all islet β-cells in the pancreas (Wucherpennig & Eisenbarth, 2001). This stage of the disease is called insulinitis. Autoimmunity against islets can be initiated early in life. Autoantibodies to multiple pancreatic beta-cell antigens such as glutamate decarboxylase (eg, GAD65), ICA512 (IA-2), and insulin are produced and detectable in the blood years before the onset of IDDM. Insulin autoantibodies usually appear first, but not always. The presence of multiple anti-isl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/28
CPCC07K16/2893A61K2039/505A61P13/10A61P3/10
Inventor L·E·阿尔托
Owner GENZYME CORP